



**Rekvina**  
LABORATORIES LIMITED

At & Post : Dashrath, N.H. No 8, Dist Baroda-391 740 (Gujarat-India)  
Admn. Office : 328-329, Third Floor, Paradise Complex, Sayajigunj, Baroda-390 005. (Gujarat-India)  
Phone : +91-265-2362966, ● Email : info@rekvinalaboratories.com ● Web : www.rekvinalaboratories.com

Date: 12<sup>th</sup> February, 2024

To,  
The Manager,  
Listing Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers Dalal Street  
28<sup>th</sup> Floor, Dalal Street, Mumbai- 400001

Company Symbol: VINRKL B  
Script Code: 526075

**Subject: Outcome of Board Meeting under Regulation 30 & 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at their meeting held on **Monday, the 12<sup>th</sup> day of February, 2024** at the registered office of the Company situated at **328 Paradise Complex Sayajigunj Baroda Vadodara, Gujarat - 390005, India** has inter- alia, Considered and approved the following matters(s):

1. Standalone Unaudited Financial Results of the Company for the Quarter and Nine months ended 31<sup>st</sup> December, 2023. A copy of the said standalone unaudited financial results along with the Limited Review Report by Statutory Auditor thereon is enclosed herewith;
2. Standalone Unaudited Financial Results of the Company for the Quarter ended 30<sup>th</sup> June, 2022. A copy of the said standalone unaudited financial results along with the Limited Review Report by Statutory Auditor thereon is enclosed herewith;

The meeting of the Board of Directors commenced at **07.45 P.M. and concluded at 08:20 P.M.**

The above information will be available on the website of company at [www.rekvinalaboratories.com](http://www.rekvinalaboratories.com)

You are requested to take the above on your records and acknowledge the same.

Thanking you,  
Yours Faithfully

For and on behalf of  
Rekvina Laboratories Limited

AMIT MUKESH SHAH  
Digitally signed  
by AMIT MUKESH  
SHAH  
Date: 2024.02.12  
20:25:11 +05'30'

Amit Mukesh Shah  
Director  
DIN: 01993211

REKVINA LABORATORIES LIMITED							
CIN: L24231GJ1988PLC011458							
Paradise Complex, 328-329, 3rd Floor, Sayajigunj, Vadodara, Gujarat, 390005							
Tel: 0265-2362966 Email-Id: info@rekvinlaboratories.com Website: www.rekvinlaboratories.com							
STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.2023							
(Rs. in Lakhs except EPS)							
PART-1							
STANDALONE							
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	9 month ended	Corresponding 9 months ended in the previous year	Previous year ended
Sr. No.	Particulars	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	<b>Income</b>						
	(a) Revenue From Operations	-	-	-	-	-	-
	(c) Other Income	-	-	-	-	-	0.38
	<b>Total Income</b>	-	-	-	-	-	0.38
2	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Finance Cost	-	-	-	-	-	0.04
	(e) Employee Benefits Expenses	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.47	0.72	0.0002	1.22	0.70	0.41
	<b>Total Expenses</b>	0.47	0.72	0.0002	1.22	0.70	0.45
	<b>Profit / (Loss) before exceptional items and tax (1-2)</b>	(0.47)	(0.72)	(0.0002)	(1.22)	(0.70)	(0.07)
3	Exceptional Items	-	-	-	-	-	-
4	<b>Profit / (Loss) before tax (3-4)</b>	(0.47)	(0.72)	(0.0002)	(1.22)	(0.70)	(0.07)
5	<b>Tax Expenses</b>						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	-	-	-	-	-	-
6	<b>Total Tax Expenses</b>	-	-	-	-	-	-
7	<b>Profit/ (Loss) for a period from continuing operations (5-7)</b>	(0.47)	(0.72)	(0.0002)	(1.22)	(0.70)	(0.07)
8	Profit/ (Loss) for a period from dis -continuing operations	-	-	-	-	-	-
9	Tax Expenses of discontinued operations	-	-	-	-	-	-
10	<b>Profit/ (Loss) for a period from dis -continuing operations (after tax) (9-10)</b>	-	-	-	-	-	-
11	<b>Other Comprehensive Income/ (Loss)</b>						
	A) (i) Amount of items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Amount of items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total Comprehensive Income for the period (comprising profit/loss) and other comprehensive income for the period (8-11-12)</b>	(0.47)	(0.72)	(0.00)	(1.22)	(0.70)	(0.07)
12	<b>Earning Per Share (For continuing operations)</b>						
	(a) Basic	-	-	-	-	-	(0.001)
	(b) Diluted	-	-	-	-	-	-
13	<b>Earning Per Share (For Discontinuing operations)</b>						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
14	<b>Earning Per Share (For continuing and discontinuing operations)</b>						
	(a) Basic	-	-	-	-	-	(0.001)
	(b) Diluted	-	-	-	-	-	-

**Notes:**

- The above results were reviewed by the Audit Committee and thereafter taken on record by the Board of Directors in their meeting on 12.02.2024 after review by an Audit Committee.
- The above results for the quarter ended on 31.12.2023 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- There were no investor complaints known to the Company outstanding at the beginning of the quarter.
- Previous period figures have been regrouped wherever necessary.

For and on behalf  
M/s Rekvina Laboratories Limited

Amit Mukesh Shah  
DIN: 01993211  
Director

Date: 12.02.2024  
Place: Gujrat



REKVINA LABORATORIES LIMITED					
CIN: CIN: L24231GJ1988PLC011458					
Registered Office: 328 PARADISE COMPLEX, SAYAJIGUNJ, VADODARA - 390005					
Statement of Standalone Unaudited Results for the Quarter ended 30/06/2022					
Particulars	Quarter Ended			(Rs. In Lacs/amount)	
	3 months ended	Preceding 3	Corresponding 3	Year ended	
	30/06/2022	months ended	months ended in	Year ended	
	(Unaudited)	31/03/2022	the previous year	31/03/2022	
			30/06/2021		
			(Unaudited)	(Audited)	
I	Revenue From Operations	-	-	-	-
II	Other Income	-	-	-	-
III	<b>Total Income (I+II)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
IV	<b>Expenses</b>				
	Cost of Materials Consumed	-	-	-	-
	Purchases of Stock-in-Trade	-	-	-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in progress	-	-	-	-
	Employee benefits expense	0.26	0.00	0.00	0.00
	Finance Costs	0.02	0.00	0.00	0.34
	Depreciation and amortisation expenses	-	-	-	-
	Other Expenses	-	0.62	0.00	7.55
	<b>Total Expenses (IV)</b>	<b>0.28</b>	<b>0.62</b>	<b>0.00</b>	<b>7.89</b>
V	Profit/(loss) before exceptional items and tax (I-IV)	-0.28	-0.62	0.00	-7.89
VI	Exceptional Items	-	-	-	-
VII	Profit/ (loss) before exceptions items and tax(V-VI)	-0.28	-0.62	0.00	-7.89
VIII	<b>Tax Expense:</b>				
	(1) Current Tax	-	-	-	-
	(2) Deferred Tax	-	-	-	-
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	-0.28	-0.62	0.00	-7.89
X	Profit/(Loss) from discontinued operations	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-
XII	Profit/(Loss) from discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(Loss) for the period (IX+XII)	-0.28	-0.62	0.00	-7.89
XIV	<b>Other Comprehensive Income</b>				
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be re classified to profit or loss	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other Comprehensive Income for the period)	-0.28	-0.62	0.00	-7.89
XVI	Earnings per equity (for Continuing operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
XVII	Earnings per equity (for discontinued operation)				
	(1) Basic	-	-	-	-0.13
	(2) Diluted	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)				
	(1) Basic	-	-	-	-0.13
	(2) Diluted	-	-	-	-

Notes:


- 1) The above results were reviewed by the Audit Committee and thereafter taken on record by the Board in its meeting held on February 12<sup>th</sup> 2024 and also the Limited review was carried out by the Statutory Auditors.
- 2) Previous year figure have been regrouped wherever necessary.
- 3) Financial Results for all the periods presented have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time

For REKVINA LABORATORIES LIMITED

Amit Shah  
Director

Date :- 12.02.2024

Place :- Vadodara



J.B.Adhyaru  
M.com, FCA

## JIGAR ADHYARU & CO. CHARTERED ACCOUNTANTS

D/5, Anil Park-2, V.I.P. Road, B/h Bright School, Karelibaug, Vadodara-18.  
Phone: (M) 099090 16771 Email: [cajigaradhyaru@gmail.com](mailto:cajigaradhyaru@gmail.com)

To  
The Board of Directors  
**Rekvina Laboratories Limited**

*Review Report on the unaudited Financial Statements pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.*


### **Opinion**


We have reviewed the accompanying statement of Unaudited Financial Results of **Rekvina Laboratories Limited** for the Quarter and Nine months ended on 31<sup>st</sup> December, 2023 ("the Statement"), being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the regulations'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For, Jigar Adhyaru & Co.  
Chartered Accountant  
FRN No. 142223W

  
(CA Jigar Adhyaru)  
(Proprietor)  
M. No. 147598



Place: Vadodara  
Date: 12<sup>th</sup> February, 2024  
UDIN: 24147598BKEAZN6300





J.B.Adhyaru  
M.com, FCA

## JIGAR ADHYARU & CO. CHARTERED ACCOUNTANTS

D/5, Anil Park-2, V.I.P. Road, B/h Bright School, Karelibaug, Vadodara-18.  
Phone: (M) 099090 16771 Email: [cajigaradhyaru@gmail.com](mailto:cajigaradhyaru@gmail.com)

To  
The Board of Directors  
**Rekvina Laboratories Limited**

*Review Report on the unaudited Financial Statements pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.*


### **Opinion**


We have reviewed the accompanying statement of Unaudited Financial Results of **Rekvina Laboratories Limited** for the Quarter and Three months ended on 30<sup>th</sup> June, 2022 ("the Statement"), being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the regulations'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Jigar Adhyaru & Co.  
Chartered Accountant  
FRN No. 142223W

  
(CA Jigar Adhyaru)  
(Proprietor)  
M. No. 147598



Place: Vadodara  
Date: 12<sup>th</sup> February, 2024  
UDIN: 24147598BKAEZO4927